CellCentric
Develops inobrodib, a first-in-class oral p300/CBP inhibitor for relapsed or refractory multiple myeloma
$220MSeries D
Role not disclosedP
Pfizer
Activity from announced rounds
Activity in this selectionthe-helm-db383296
- Rounds participated in
- 1
- Confirmed lead rounds
- — 1 roles undisclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $220M 1 disclosed · full round size, not this investor’s share